5 completed. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 5 |
Follow Visudyne: new trials by email Literature Review of Visudyne trials Research Report on Visudyne
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Ranibizumab 0.5mg, Ranibizumab 0.5 mg, Verteporfin PDT - Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM) | Phase 3 | Completed | Novartis Pharmaceuticals | 457 | 2013-09-11 | 2019-06-24 |
| VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration) Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321), Visudyne - Macular Degeneration | Phase 3 | Completed | Bayer | 304 | 2011-12-01 | 2016-11-04 |
| Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo - Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Novartis | 321 | 2007-02-01 | 2011-04-19 |
| Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV intravitreal ranibizumab, intravitreal ranibizumab & photodynamic therapy - Choroidal Neovascularization, Age-Related Macular Degeneration | Phase 3 | Completed | University Hospital, Basel, Switzerland | 40 | 2006-07-01 | 2009-04-07 |
| A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide - Macular Degeneration, Choroidal Neovascularization | Phase 3 | Completed | Novartis Pharmaceuticals | 111 | 2005-09-01 | 2016-03-31 |
Choroidal Neovascularization (4) · Macular Degeneration (4)
Novartis Pharmaceuticals (2) · Bayer (1) · Novartis (1) · University Hospital, Basel, Switzerland (1)
China (2) · United States (2) · Canada (1) · Hong Kong (1) · India (1) · Philippines (1) · South Korea (1) · Switzerland (1) · Thailand (1)